Dr. Jack Cush reviews the news and journal articles from this past week in RheumNow.com. Interesting reports this week about dementia, who gets hand OA and a great list of women Heroes and Pillars of Rheumatology.
The integration of Telemedicine in to rheumatologic care was ignited by pandemic restrictions in early 2020 and since the advantages and disadvantages have been debated.
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. He discusses the GI side effects of IL-17 inhibitors, downstream revenues from rheumatology care and dietary prevention of gout.
The ACR has updated its clinical guidance for the use of COVID-19 vaccination in patients with musculoskeletal disorders (MSK).
Summary of Guidance documents and versions
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week a trifecta of Gout reports and the last word on the ORAL Surveillance study...
For adults aged ≥18 years who received 2 doses of an mRNA COVID-19 vaccine, a third dose increased vaccine effectiveness (prevention of hospitalization) among adults without (82% to 97%) and with immunocompromising conditions (69% to 88%), with near similar efficacy.
I avoided getting infected with SARS-CoV2 for over 2 years. Now that I have it, I tried to figure out what I should do.
ARD has publish a prospective, multicenter, observational study of vaccination outcomes in antineutrophil cytoplasmic antibodies associated vasculitis (AAV) patients, showing that AAV patients may not be adequately protected after standard two-dose COVID-19 vaccination, but that a third
Patients with ANCA-associated vasculitis (AAV) did not mount durable antibody responses to the SARS-CoV-2 Delta variant after the standard two-dose regimen of the Pfizer-BioNTech vaccine -- and for those taking rituximab (Rituxan) as maintenance therapy, even a third dose wasn't much help.
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogren's.
While the American College of Rheumatology (ACR) recommends holding mycophenolate (MMF) in rheumatic and musculoskeletal diseases (RMD) patients receiving COVID-19 vaccines, there is limited data on such an approach.
Eric Dein @ericdeinmd ( View Tweet )
Leonard Calabrese @LCalabreseDO ( View Tweet )
TheDaoIndex @KDAO2011 ( View Tweet )
